• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Curis Inc.

    4/24/26 7:13:45 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRIS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    CURIS, INC.

    (Name of Issuer)


    Common Stock, Par Value $0.01 per share

    (Title of Class of Securities)




    231269309

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    231269309


    1Names of Reporting Persons

    Nantahala Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,215,165.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,215,165.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,215,165.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA, HC

    Comment for Type of Reporting Person:  Explanatory Note: This filing replaces the Schedule 13G/A filed on April 7, 2026 which was mistakenly identified as Amendment No. 2. The reporting persons had not previously filed a Schedule 13G with respect to CURIS, INC.


    SCHEDULE 13G

    CUSIP Number(s):
    231269309


    1Names of Reporting Persons

    Wilmot B. Harkey
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,215,165.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,215,165.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,215,165.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    231269309


    1Names of Reporting Persons

    Daniel Mack
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,215,165.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,215,165.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,215,165.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CURIS, INC.
    (b)Address of issuer's principal executive offices:

    128 Spring Street, Building C - Suite 500, Lexington, MA 02421
    Item 2. 
    (a)Name of person filing:

    (1) Nantahala Capital Management, LLC ("Nantahala") (2) Wilmot B. Harkey (3) Daniel Mack (together the "Reporting Persons")
    (b)Address or principal business office or, if none, residence:

    130 Main St. 2nd Floor, New Canaan, CT 06840
    (c)Citizenship:

    (1) Nantahala is a Massachusetts limited liability company. (2) Each of Messrs. Harkey and Mack is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, Par Value $0.01 per share
    (e)CUSIP Number(s):

    231269309
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of March 31, 2026, Nantahala may be deemed to be the beneficial owner of 4,215,165 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares The 4,215,165 Shares includes 2,215,165 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of warrants
    (b)Percent of class:

    As of March 31, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the following percentage of the total number of Shares outstanding based on 39,978,693 shares outstanding received from the issuer on Form 10-K filed on March 24, 2026: (1) Nantahala Capital Management, LLC ("Nantahala") : 9.99% (2) Wilmot B. Harkey: 9.99% (3) Daniel Mack: 9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.

     (ii) Shared power to vote or to direct the vote:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 4,215,165 Shares. (2) Wilmot B. Harkey: 4,215,165 Shares. (3) Daniel Mack: 4,215,165 Shares.

     (iii) Sole power to dispose or to direct the disposition of:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.

     (iv) Shared power to dispose or to direct the disposition of:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 4,215,165 Shares. (2) Wilmot B. Harkey: 4,215,165 Shares. (3) Daniel Mack: 4,215,165 Shares.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of more than five percent of the outstanding shares of common stock beneficially owned by Nantahala reported herein. BLACKWELL PARTNERS LLC - SERIES A, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of more than five percent of the outstanding shares of common stock beneficially owned by Nantahala reported herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E). See Item 4(a).
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Nantahala Capital Management, LLC
     
    Signature:/s/ Taki Vasilakis
    Name/Title:Taki Vasilakis / Chief Compliance Officer
    Date:04/24/2026
     
    Wilmot B. Harkey
     
    Signature:/s/ Wilmot B. Harkey
    Name/Title:Wilmot B. Harkey / Manager
    Date:04/24/2026
     
    Daniel Mack
     
    Signature:/s/ Daniel Mack
    Name/Title:Daniel Mack / Manager
    Date:04/24/2026
    Get the next $CRIS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRIS

    DatePrice TargetRatingAnalyst
    5/19/2025$17.00Buy
    H.C. Wainwright
    11/17/2023$26.00Buy
    Truist
    4/4/2022Outperform → Mkt Perform
    Raymond James
    10/13/2021$15.00Outperform
    Raymond James
    More analyst ratings

    $CRIS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Curis Inc.

    SCHEDULE 13G - CURIS INC (0001108205) (Subject)

    4/24/26 7:13:45 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Curis Inc.

    DEF 14A - CURIS INC (0001108205) (Filer)

    4/21/26 4:52:40 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form PRE 14A filed by Curis Inc.

    PRE 14A - CURIS INC (0001108205) (Filer)

    4/10/26 4:19:53 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Curis Provides Fourth Quarter 2025 Business Update

    Management to host conference call today at 4:30 p.m. ETLEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2025. Operational HighlightsTakeAim LymphomaLakshmi Nayak, MD, Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute in Boston, presented a poster with updated clinical data in Primary CNS Lymphoma (PCNSL

    3/19/26 4:00:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026

    LEXINGTON, Mass., March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its fourth quarter 2025 financial and operating results on Thursday, March 19, 2026, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio

    3/12/26 4:27:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

    Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.

    1/9/26 8:00:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kaitin Kenneth I

    4 - CURIS INC (0001108205) (Issuer)

    4/1/26 7:51:27 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Zung Jonathan B.

    4 - CURIS INC (0001108205) (Issuer)

    3/23/26 4:03:59 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Hamdy Ahmed Md

    4 - CURIS INC (0001108205) (Issuer)

    3/23/26 4:03:44 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Curis with a new price target

    H.C. Wainwright resumed coverage of Curis with a rating of Buy and set a new price target of $17.00

    5/19/25 8:52:11 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist initiated coverage on Curis with a new price target

    Truist initiated coverage of Curis with a rating of Buy and set a new price target of $26.00

    11/17/23 7:37:50 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis downgraded by Raymond James

    Raymond James downgraded Curis from Outperform to Mkt Perform

    4/4/22 11:27:43 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Financials

    Live finance-specific insights

    View All

    Curis Provides Fourth Quarter 2025 Business Update

    Management to host conference call today at 4:30 p.m. ETLEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2025. Operational HighlightsTakeAim LymphomaLakshmi Nayak, MD, Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute in Boston, presented a poster with updated clinical data in Primary CNS Lymphoma (PCNSL

    3/19/26 4:00:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026

    LEXINGTON, Mass., March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its fourth quarter 2025 financial and operating results on Thursday, March 19, 2026, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio

    3/12/26 4:27:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025

    LEXINGTON, Mass., Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast

    10/30/25 4:00:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Leadership Updates

    Live Leadership Updates

    View All

    Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations

    LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of three new executives to its management team. Joining the company, are Felix Geissler, M.D., Ph.D., as Vice President of Medical Affairs, Kimberly Steinmann, M.D., as Vice President of Clinical Development, and Dora Ferrari, as Vice President of Clinical Operations. They will be reporting directly to Dr. Reinhard von Roemeling, Senior Vice President, Clinical Devel

    1/3/22 8:00:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Appoints John A. Hohneker, M.D. To Board Of Directors

    LEXINGTON, Mass., Dec. 6, 2021  /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of John A. Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings 30 years of drug development and leadership experience within the biotech and pharmaceutical industries.  He most recently served as President and CEO of Anokion SA. Prior to Anokion, he was President of Research and Development at FORMA Therapeutics Inc., where he guided the company's transitio

    12/6/21 8:00:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Jan. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 4, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 185,000 shares of Curis common stock to three new employees, with a grant date of January 4, 2021 (the "Q1 2021 Inducement Grants"). Each of the Q1 2021 Inducement Grants has an exercise price per share equal to the closing price of the Company's common stock on January 4, 2021. Each stock option has a 10 year term and vests ov

    1/8/21 4:01:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Curis Inc.

    SC 13G/A - CURIS INC (0001108205) (Subject)

    11/13/24 2:05:06 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Curis Inc.

    SC 13G - CURIS INC (0001108205) (Subject)

    11/1/24 4:35:37 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Curis Inc.

    SC 13G - CURIS INC (0001108205) (Subject)

    4/15/24 2:12:19 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care